BioPharmSignal logoBioPharmSignal

Biotech News

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.Clinical readout

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC

Related news

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ORICOric Pharmaceuticals, Inc.2026-10-02 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

View all latest news

Oric Pharmaceuticals, Inc.

Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is...

Recent company news

ORICOric Pharmaceuticals, Inc.2026-10-02 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-09-04 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-09-02 20:05 EST

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORICOric Pharmaceuticals, Inc.2026-08-07 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Stock data

Close
12.52 USD
Market cap
788.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States